A New Cu2+-Binding Isoxazole‑Based N‑Acylhydrazone as a MAO-B Inhibitor: Dual Activity for the Management of Neurodegenerative Diseases

Synthesis and evaluation of MIXX1, a new isoxazole-derived ligand, as a multitarget candidate for Alzheimer's disease treatment. MIXX1 selectively inhibits MAO-B (45.4% at 100 µM) over MAO-A (3.2%), and acts as a Cu(II) chelator, forming an ML₂ complex as revealed by spectroscopic titration. This metal-binding ability suggests MIXX1 could compete with β-amyloid peptides for Cu²⁺ ions, potentially suppressing ROS generation. The combination of selective enzyme inhibition and metal attenuation highlights MIXX1 as a promising scaffold for further development in neurodegenerative disease management.